Charles River Biopharmaceutical Services (BPS) delivers client-focused solutions for the specific testing and manufacturing requirements of your biologic. We provide tailored global testing and manufacturing services to help accelerate drug development from concept to product release.
BPS has the capabilities to address the needs of companies based anywhere in the world. Our BPS facilities in the U.S., U.K., Ireland, and Germany are part of a global scientific network, offering products and services that span the entire drug development process. Furthermore, BPS has agents in Australia, Japan, India, Korea, Singapore, and Taiwan to support our clients around the world.
We aim to make it easy to work with us, and to that end, BPS provides you with more flexibility, experience and expertise in multiple regulatory environments to accelerate the development of your biologic, enabling you to get your product to market faster.
BPS follows international regulatory guidelines for testing and clinical-scale manufacturing of biologics. The assays provided range from cell characterization and process-validation studies through to stability and product-release testing. Manufacturing services include cell banking, storage, fill and finish, and viral vaccine and antisera production.
Areas of expertise include:
- Cell banking and characterization
- Product characterization
- Process characterization (residual testing)
- Vaccines and cell therapy
- Viral clearance and TSE studies
- Lot release testing
- Stability testing
- In vivo biosafety and potency testing
- Discovery and development
- Polyclonal antisera production
We have recently expanded our Ireland facility to offer biosafety level 2(BSL-2) in vivo challenge studies (bacterial & viral). The new self-contained, high-biosecurity shower-in unit includes 12 new animal rooms, allowing for increased capacity ideal for long-term vaccine and immunogenicity.